Resverlogix's receives licensing agreement offer for ReVas program

By Angela McDaniels

Seattle, Dec. 22 - Resverlogix Corp. said a medical technology organization has expressed interest in forming a license agreement with the company for Resverlogix's ReVas small molecule program.

The program is focused on the development of compounds for use in drug-eluting stents and medical devices. The intent of the unnamed organization is to use the technology for the treatment of restenosis, a complication of invasive cardiovascular surgery.

Resverlogix said its board of directors will review the license agreement and term sheet during the holiday period and announce its intentions in 2006.

Resverlogix is a biotechnology company based in Calgary, Alta.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.